Monday, November 9, 2026

USD/EUR Rises By 1% In The Last 10 Sessions

USD/EUR Rises By 1% In The Last 10 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 1.26% for the last 10 sessions. At 15:09 EST on Wednesday, 5 July, USD/EUR (USDEUR) is $0.92.

USD/EUR's yearly highs and lows, it's 2.185% up from its 52-week low and 12.126% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was a positive 0.21%, a negative 0.08%, and a positive 0.33%, respectively.

USD/EUR's highest amplitude of average volatility was 0.21% (last week), 0.32% (last month), and 0.33% (last quarter), respectively.

News about

  • Usd/jpy technical analysis: selling operations May occur at any time - 03 July 2023. According to DailyForex on Monday, 3 July, "On the economic side, the USD/JPY currency pair is trading affected by the results of the latest economic data this morning. ", "The price of the USD/JPY currency pair jumped to the 145.06 resistance level above It is more than seven months old, and it is settling around 144.70 at the time of writing. "
  • Usd/jpy defends 100-hour sma, trades with a mild positive bias below mid-144.00s. According to FXStreet on Monday, 3 July, "The USD/JPY pair struggles to gain any meaningful traction on Monday and oscillates in a narrow trading band, just above the 100-hour Simple Moving Average (SMA) through the Asian session. ", "In the meantime, traders might refrain from placing aggressive directional bets around the USD/JPY pair."
  • Usd/jpy signal: potential buying opportunity today - 03 July 2023. According to DailyForex on Monday, 3 July, "This discrepancy favors continued upward momentum in the USD/JPY pair over the long term. ", "The bullish patterns and interest rate differentials suggest a favorable long-term outlook for the USD/JPY pair. "
  • Usd/jpy trades with a mild negative bias around mid-144.00s, downside seems cushioned. According to FXStreet on Tuesday, 4 July, "The USD/JPY pair struggles to capitalize on the previous day's positive move back closer to the 145.00 psychological mark and edges lower during the Asian session on Tuesday. ", "That said, expectations that the BoJ will stick to its ultra-ease monetary policy stance keep a lid on any meaningful gains for the JPY and lend some support to the USD/JPY pair. "
  • Usd/jpy hovers around mid-144.00s as yields flag recession, Japan intervention looms. According to FXStreet on Tuesday, 4 July, "Also challenging the USD/JPY buyers are the fears of recession signaled via the US Treasury bond yields inversion.", "Moving on, the US holiday will restrict immediate USD/JPY moves but the fears of market intervention can check the bullish bias despite hawkish Fed bets, favoring a 0.25% rate hike in July."

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com